Vitrolife Group (VITR) investor relations material

Executive summary

• Organic sales growth of 5% in local currencies, with SEK 807 million in net sales, though reported sales declined 4% in SEK due to currency effects.

• Gross margin reached 59.9%, one of the highest in recent quarters, driven by favorable product and market mix, up 2.5 percentage points year-over-year.

• EBITDA margin improved to 31.1%, with net income stable at SEK 101 million and EPS at SEK 0.74.

• Strong performance in North America and APAC, offset by significant declines in the Middle East due to geopolitical instability.

• Restructuring program on track, with main savings expected from Q2 and full impact by end of Q3 2026.

Financial highlights

• Net sales: SEK 807 million, 5% organic growth in local currencies, but -4% reported due to 9% negative currency impact.

• Gross income: SEK 483 million, gross margin 59.9% (up from 57.4%).

• EBITDA: SEK 251 million, margin 31.1% (up from 30.6%).

• Net income: SEK 101 million; EPS: SEK 0.74.

• Operating cash flow: SEK 172 million, up from SEK 69 million last year.

• Net debt/EBITDA improved to 0.6 from 0.7.

• Proposed dividend: SEK 1.10 per share.

Outlook and guidance

• Expectation of continued strong performance in North America, with potential for further acceleration in Q3 due to favorable comps.

• APAC shows signs of recovery but remains volatile; cautious optimism for sustained growth.

• Gross margin expected to remain strong, supported by ongoing focus on profitable products and regions.

• Restructuring program savings to materialize from Q2 and Q3 onward, with full impact by end of Q3 2026.

• Long-term objectives: annual organic growth >10%, EBITDA margin >33%, net debt/EBITDA <3.